The Hunt for an Alzheimer’s Cure: What Science Knows, What It Has Tried, and What Is Still Unknown
Science | May 23, 2026
The search for Alzheimer’s disease drug targets has generated more clinical trial failures than any other area of modern medicine, yet the field produced its first meaningful disease-modifying therapies only in the past three years. More than 55 million people worldwide live with the condition, and understanding why progress has been so slow requires going back to what actually happens inside the brain.
What Happens in an Alzheimer’s Brain
Alzheimer’s disease is defined at the cellular level by two kinds of abnormal deposits: amyloid plaques and tau tangles.
Amyloid plaques form when fragments of a protein called amyloid-beta clump together between neurons, disrupting cell communication. These fragments are cut from a larger precursor protein by enzymes called secretases. In a healthy brain, amyloid-beta is produced and cleared continuously. In Alzheimer’s, this clearing process fails, and over years and decades, the fragments accumulate into sticky plaques.
Tau tangles form inside neurons rather than between them. Tau is a protein that normally helps stabilise the internal scaffolding of a neuron. In Alzheimer’s disease, tau becomes chemically modified through a process called hyperphosphorylation, causing it to detach from the scaffolding and clump into dense filaments called neurofibrillary tangles. These tangles kill the neurons from the inside.
The two pathologies tend to appear in sequence. Amyloid plaques typically accumulate first, often by 15 to 20 years before symptoms appear. Tau tangles follow, spreading through the brain in a pattern that correlates closely with the cognitive symptoms patients experience.
The Amyloid Hypothesis and Its Long Dominance
For most of the past three decades, the dominant research framework in Alzheimer’s science has been the amyloid hypothesis: the idea that amyloid accumulation is the root cause of the disease, and that clearing or preventing plaques should, in theory, slow or stop cognitive decline.
The hypothesis generated an enormous number of drug trials. The vast majority failed. Dozens of compounds successfully reduced amyloid in patients’ brains while producing no measurable clinical benefit, a paradox that led some researchers to conclude that amyloid was a symptom rather than a cause, or that interventions were arriving too late in the disease course to make a difference.
The amyloid hypothesis was not abandoned, but it was significantly revised. Current thinking holds that amyloid accumulation is a necessary but not sufficient condition for the disease, that tau pathology is more directly tied to neuron death and symptom progression, and that the relationship between the two involves a complex web of additional factors including neuroinflammation, lipid metabolism, and synaptic failure.
The Genetics: APOE4 and Its Many Consequences
The strongest known genetic risk factor for late-onset Alzheimer’s, accounting for more than half of all cases, is a variant of the apolipoprotein E gene called APOE4.
APOE is a protein that manages lipid transport throughout the body and, critically, in the brain. There are three common variants of the gene, labelled epsilon-2, epsilon-3, and epsilon-4. The epsilon-3 variant is carried by most people. The epsilon-2 variant appears to be somewhat protective. The epsilon-4 variant, APOE4, carries dramatically elevated risk: having one copy increases Alzheimer’s risk two to four times; having two copies pushes that risk to eight to sixteen times.
The mechanisms by which APOE4 drives disease are numerous and still being worked out. APOE4 impairs the brain’s clearance of amyloid-beta, meaning plaques accumulate faster and are harder to remove. It interacts with tau directly, accelerating the phosphorylation that causes tau tangles to form and spread. It disrupts lipid metabolism inside neurons, impairing the synaptic function that underlies memory and cognition. It promotes neuroinflammation by activating the brain’s immune cells, called microglia, in ways that damage rather than protect neurons. And recent 2025 research has found that APOE4 carriers may have heightened vulnerability to stress hormones, which can accelerate tau pathology through mitochondrial dysfunction.
The sheer breadth of APOE4’s effects makes it simultaneously the most promising and most complicated target in Alzheimer’s research. It is involved in so many disease pathways that blocking or modifying it could, in principle, address the disease at multiple points simultaneously. The difficulty is that APOE plays essential functions throughout the body, meaning that broad interference with its activity risks unintended consequences.
What the First Treatments Achieved
Two anti-amyloid antibody drugs have received FDA approval for early Alzheimer’s disease: lecanemab, approved in July 2023, and donanemab, approved in July 2024. Both work by binding to amyloid-beta in the brain and tagging it for removal by the immune system.
In clinical trials, both drugs successfully reduced amyloid burden in participants’ brains. They also slowed cognitive decline by 25 to 30 percent over 18-month trial periods compared to placebo. Donanemab’s long-term extension data, published in 2025, showed that benefits persisted up to three years, with more than 75 percent of treated patients achieving amyloid clearance within 76 weeks.
These are not trivial results. A 25 to 30 percent slowing of decline, for a disease that currently has no effective treatment, represents meaningful clinical benefit. But the language that matters is “slowing decline.” Neither drug restores memory, reverses existing damage, or halts the disease outright. Patients continue to decline; they decline somewhat more slowly.
Both drugs also carry serious risks. The most significant is amyloid-related imaging abnormalities, known as ARIA, which refers to brain swelling or micro-bleeds detectable on MRI. ARIA occurs more frequently in APOE4 carriers, the very patients who tend to have the most severe disease. Regulatory bodies have navigated this with genetic testing requirements and monitoring protocols, but the risk profile limits how broadly these drugs can be used.
The European Medicines Agency approved lecanemab with genetic restrictions. It rejected donanemab entirely, citing an unfavourable benefit-risk assessment, a decision that reflects the genuine uncertainty about where these drugs sit on the risk-benefit spectrum.
The IDOL Enzyme: A New Alzheimer’s Disease Drug Target
Against this backdrop, the February 2026 publication of research from Indiana University School of Medicine on an enzyme called IDOL opened a different line of attack.
The study, led by Hande Karahan and Jungsu Kim, used two animal models of Alzheimer’s disease in which the IDOL gene was removed from neurons. The results were striking. Removing neuronal IDOL significantly reduced amyloid plaques. It also lowered levels of APOE protein in the brain, addressing the root genetic risk factor rather than its downstream effects. And it improved two processes closely tied to brain resilience: neuron-to-neuron communication and lipid metabolism.
The significance of targeting IDOL in neurons, rather than in microglia or other cell types, is that it places the intervention at the source of the problem. APOE4 exerts many of its harmful effects through neurons directly. An enzyme with a defined active site that can be targeted with small molecules, which is what IDOL is, is in principle more tractable for drug development than trying to replace or silence a gene.
The research is still in animal models. Whether the findings translate to humans, and whether the benefit-risk profile is acceptable when neuronal IDOL is targeted therapeutically, remains to be established. The path from a promising target in mice to an FDA-approved drug typically takes 10 to 15 years and fails more often than it succeeds. But the mechanism is novel, the target is biologically well-defined, and the connection to APOE, the central genetic driver of the disease, gives it a scientific rationale that many previous targets lacked.
What Is Still Unknown
Despite 40 years of intensive research, the fundamental question of what causes Alzheimer’s disease remains contested.
The amyloid cascade hypothesis has generated the only approved disease-modifying treatments, but neither lecanemab nor donanemab comes close to stopping the disease. This either means the hypothesis is correct but intervention is arriving too late, or it means amyloid is one contributor among several and clearing it alone is insufficient.
The tau hypothesis, that tau tangles are the more direct cause of neuronal death and cognitive symptoms, has strong observational support but limited therapeutic demonstration. Anti-tau drugs have performed poorly in trials to date, though researchers argue that targeting tau earlier in the disease course, before tangles are established, may produce better results.
The neuroinflammation hypothesis holds that chronic activation of the brain’s immune cells is a primary driver of neuron loss, not a secondary response to plaques and tangles. This is gaining research momentum, but the clinical validation is thin.
The precise timing question, at what point interventions need to begin to affect outcomes, is central to all of this. The fact that amyloid accumulates 15 to 20 years before symptoms appear raises the possibility that the disease needs to be treated years before a patient feels anything, which creates enormous challenges for clinical trial design and for the economics of treatment.
The Diagnosis Problem: Biomarkers and Blood Tests
Effective treatment depends on catching the disease early. This has historically meant expensive and inaccessible tests. PET scanning, which can image amyloid deposits in living brains, costs between $3,000 and $8,000 and is not covered by standard insurance for most patients. Lumbar punctures, which can measure amyloid-beta and tau in cerebrospinal fluid, are invasive and require specialist facilities. Neither was practical for large-scale screening in primary care.
Blood-based biomarkers have changed this calculus significantly over the past two years. Tests that measure phosphorylated tau-217, a form of tau that appears in the blood before symptoms manifest, have been validated in large-scale studies with accuracy rates exceeding 90 percent for identifying early Alzheimer’s pathology. The FDA cleared the first such blood test for clinical use in 2024. By 2026, several commercial laboratories offer versions of these assays, and clinical guidance from major neurology associations now supports their use in diagnostic workups for patients with cognitive complaints.
The practical significance is that researchers can now identify people with presymptomatic Alzheimer’s at scale, which is prerequisite for running the prevention trials that would test whether treating the disease before symptoms appear produces better outcomes than treating it after. Without cheap, accessible biomarkers, those trials were logistically impossible to recruit for. With them, the field can begin to answer the question that has haunted every treatment trial to date: are we starting too late?
The same biomarkers are also reshaping clinical prescribing of lecanemab and donanemab. Both drugs are indicated only for patients with confirmed amyloid pathology, which previously required an expensive PET scan before treatment. Blood tests that confirm amyloid burden at a fraction of the cost make the drugs accessible to a far larger patient population, though insurance coverage policies have lagged behind the science.
The Path Forward
The year 2026 represents, by historical standards, an unusually productive moment in Alzheimer’s research. The first disease-modifying drugs are in clinical use. Blood-based biomarkers have been validated, making it possible to detect amyloid and tau abnormalities with a simple blood draw rather than a PET scan or spinal tap, which lowers the barrier for early diagnosis. New targets like IDOL are entering the research pipeline with novel mechanisms that could address the disease at the level of its core genetic risk.
None of this amounts to a cure. The 55 million people currently living with Alzheimer’s are unlikely to benefit from any of the research now in early stages. But the scientific understanding of the disease is deeper, broader, and more mechanistically grounded than it has been at any previous point. The question is whether that understanding can be translated into treatments that do more than slow the clock.
Sources: IDOL enzyme Alzheimer’s research, Neuroscience News | Scientists uncover new Alzheimer’s drug target, SciTechDaily | IDOL enzyme study, IU School of Medicine | ApoE in Alzheimer’s pathophysiology, PMC | Lecanemab approval, Alzheimer’s Association | Donanemab approval, Alzheimer’s Association | Anti-amyloid therapies progress, PMC | Expanding the Alzheimer’s treatment landscape 2026, BrightFocus
